Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.

被引：0
|
作者：
Jimenez, B.
Trigo Perez, J. M.
Saez Medina, M. I.
Quero Blanco, C.
Pajares, B.
Rueda, A.
Alba, E.
机构：
[1] Hosp Univ Virgen de la Victoria, Malaga, Spain
[2] Hosp Costa del Sol, Marbella, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5594
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients
    Jimenez, Begona
    Trigo, Jose M.
    Pajares, Bella I.
    Saez, Maria I.
    Quero, Cristina
    Navarro, Victor
    Llacer, Casilda
    Medina, Laura
    Rueda, Antonio
    Alba, Emilio
    ORAL ONCOLOGY, 2013, 49 (02) : 182 - 185
  • [2] Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer
    M. Tahara
    H. Minami
    Y. Hasegawa
    K. Tomita
    A. Watanabe
    K. Nibu
    M. Fujii
    Y. Onozawa
    Y. Kurono
    D. Sagae
    T. Seriu
    M. Tsukuda
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 769 - 776
  • [3] Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer
    Tahara, M.
    Minami, H.
    Hasegawa, Y.
    Tomita, K.
    Watanabe, A.
    Nibu, K.
    Fujii, M.
    Onozawa, Y.
    Kurono, Y.
    Sagae, D.
    Seriu, T.
    Tsukuda, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 769 - 776
  • [4] Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer
    Abdella, M.
    AbdelHalim, I.
    ELSheneshawy, H.
    ELSherbiny, E.
    ElKholy, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 303 - 303
  • [5] Weekly Paclitaxel plus Cetuximab in the primary treatment of metastatic/recurrent squamous cell cancer of head and neck
    Taira, Shinichiro
    Nakano, Kenji
    Tomomatsu, Junichi
    Marshall, Shouko
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [7] Weekly Versus Tri-Weekly Paclitaxel and Carboplatin in Combination with Cetuximab in Recurrent/Metastatic Head and Neck Cancer Patients: a Toxicity Analysis
    Geraghty, L.
    Hoffman, S.
    Schultz, T.
    Porter, K.
    Issa, M.
    Rupert, R.
    Bhateja, P.
    Old, M.
    Rocco, J. W.
    Blakaj, D. M.
    Bonomi, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1199 - 1199
  • [8] Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
    Geraghty, Leeann
    Schultz, Thomas E.
    Hoffman, Sarah E.
    Porter, Kyle
    Issa, Majd
    Karivedu, Vidhya
    Bonomi, Marcelo
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (05)
  • [9] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [10] The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
    Tejani, Mohamedtaki A.
    Cohen, Roger B.
    Mehra, Ranee
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 173 - 185
12345